Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Immunocore Holdings (IMCR) Non-Current Receivables (2020 - 2023)

Immunocore Holdings' Non-Current Receivables history spans 4 years, with the latest figure at $63.2 million for Q3 2023.

  • On a quarterly basis, Non-Current Receivables rose 30.86% to $63.2 million in Q3 2023 year-over-year; TTM through Sep 2023 was $63.2 million, a 30.86% increase, with the full-year FY2022 number at $54.8 million, up 167.25% from a year prior.
  • Non-Current Receivables hit $63.2 million in Q3 2023 for Immunocore Holdings, up from $60.6 million in the prior quarter.
  • Over the last five years, Non-Current Receivables for IMCR hit a ceiling of $63.2 million in Q3 2023 and a floor of $12.2 million in Q1 2021.
  • Historically, Non-Current Receivables has averaged $36.6 million across 4 years, with a median of $39.5 million in 2022.
  • Biggest five-year swings in Non-Current Receivables: skyrocketed 225.35% in 2022 and later surged 30.86% in 2023.
  • Tracing IMCR's Non-Current Receivables over 4 years: stood at $13.6 million in 2020, then soared by 51.03% to $20.5 million in 2021, then skyrocketed by 167.25% to $54.8 million in 2022, then rose by 15.32% to $63.2 million in 2023.
  • Business Quant data shows Non-Current Receivables for IMCR at $63.2 million in Q3 2023, $60.6 million in Q2 2023, and $54.9 million in Q1 2023.